Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Solid Tumors with HRD
NCT03274661Phase 2Completed
- Sponsor
- Baptist Health South Florida
- Start
- Nov 2017
- Primary completion
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in solid tumor and endometrial carcinoma, sponsored by Baptist Health South Florida. Primary endpoint: Immune-Related Objective Response Rate at 20 weeks. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
solid tumorendometrial carcinoma
Beyond the preview
Go deeper on NCT03274661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274661.